Tm Bioscience Licenses CYP450 SNP in Bid for 510(k) to Rival Roche; Also Plans Warfarin Dx | GenomeWeb

Tm Bioscience is gearing up to take on Roche Molecular Diagnostics' AmpliChip CYP450 assay, and it hopes to produce a diagnostic to help guide dosing with the anticoagulant warfarin, which may rival a test being developed by Third Wave Technologies.

"Our goal is to take all of those assays â€" and we'll have five cytochrome P450 assays, including the warfarin assay â€" and we intend to submit four of them this year for FDA approval," said Tm Bioscience CEO Greg Hines in an interview with Pharmacogenomics Reporter last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.